|
1
|
Granero-Moltó F, Weis JA, Miga MI, Landis
B, Myers TJ, O'Rear L, Longobardi L, Jansen ED, Mortlock DP and
Spagnoli A: Regenerative effects of transplanted mesenchymal stem
cells in fracture healing. Stem Cells. 27:1887–1898. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marie PJ and Fromigué O: Osteogenic
differentiation of human marrow-derived mesenchymal stem cells.
Regen Med. 1:539–548. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Koehler KC, Alge DL, Anseth KS and Bowman
CN: A Diels-Alder modulated approach to control and sustain the
release of dexamethasone and induce osteogenic differentiation of
human mesenchymal stem cells. Biomaterials. 34:4150–4158. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yokota J, Chosa N, Sawada S, Okubo N,
Takahashi N, Hasegawa T, Kondo H and Ishisaki A: PDGF-induced
PI3K-mediated signaling enhances the TGF-β-induced osteogenic
differentiation of human mesenchymal stem cells in a
TGF-β-activated MEK-dependent manner. Int J Mol Med. 33:534–542.
2014.PubMed/NCBI
|
|
5
|
Tsuji K, Bandyopadhyay A, Harfe BD, Cox K,
Kakar S, Gerstenfeld L, Einhorn T, Tabin CJ and Rosen V: BMP2
activity, although dispensable for bone formation, is required for
the initiation of fracture healing. Nat Genet. 38:1424–1429. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lin L, Fu X, Zhang X, Chen LX, Zhang JY,
Yu CL, Ma KT and Zhou CY: Rat adipose-derived stromal cells
expressing BMP4 induce ectopic bone formation in vitro and in vivo.
Acta Pharmacol Sin. 27:1608–1615. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kotajima S, Kishimoto KN, Watanuki M,
Hatori M and Kokubun S: Gene expression analysis of ectopic bone
formation induced by electroporatic gene transfer of BMP4. Ups J
Med Sci. 111:231–241. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kugimiya F, Kawaguchi H, Kamekura S,
Chikuda H, Ohba S, Yano F, Ogata N, Katagiri T, Harada Y, Azuma Y,
et al: Involvement of endogenous bone morphogenetic protein (BMP) 2
and BMP6 in bone formation. J Biol Chem. 280:35704–35712. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tsuji K, Cox K, Gamer L, Graf D,
Economides A and Rosen V: Conditional deletion of BMP7 from the
limb skeleton does not affect bone formation or fracture repair. J
Orthop Res. 28:384–389. 2010.PubMed/NCBI
|
|
10
|
Levet S, Ciais D, Merdzhanova G, Mallet C,
Zimmers TA, Lee SJ, Navarro FP, Texier I, Feige JJ, Bailly S and
Vittet D: Bone morphogenetic protein 9 (BMP9) controls lymphatic
vessel maturation and valve formation. Blood. 122:598–607. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kang Q, Song WX, Luo Q, Tang N, Luo J, Luo
X, Chen J, Bi Y, He BC, Park JK, et al: A comprehensive analysis of
the dual roles of BMPs in regulating adipogenic and osteogenic
differentiation of mesenchymal progenitor cells. Stem Cells Dev.
18:545–559. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shi Y and Massagué J: Mechanisms of
TGF-beta signaling from cell membrane to the nucleus. Cell.
113:685–700. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Foletta VC, Lim MA, Soosairajah J, Kelly
AP, Stanley EG, Shannon M, He W, Das S, Massague J and Bernard O:
Direct signaling by the BMP type II receptor via the cytoskeletal
regulator LIMK1. J Cell Biol. 162:1089–1098. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lavery K, Swain P, Falb D and
Alaoui-Ismaili MH: BMP-2/4 and BMP-6/7 differentially utilize cell
surface receptors to induce osteoblastic differentiation of human
bone marrow-derived mesenchymal stem cells. J Biol Chem.
283:20948–20958. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ali IH and Brazil DP: Bone morphogenetic
proteins and their antagonists: Current and emerging clinical uses.
Br J Pharmacol. 171:3620–3632. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Passa O, Tsalavos S, Belyaev NN, Petryk A,
Potocnik AJ and Graf D: Compartmentalization of bone morphogenetic
proteins and their antagonists in lymphoid progenitors and
supporting microenvironments and functional implications.
Immunology. 134:349–359. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yanagita M: Antagonists of bone
morphogenetic proteins in kidney disease. Curr Opin Investig Drugs.
11:315–322. 2010.PubMed/NCBI
|
|
18
|
Dean DB, Watson JT, Moed BR and Zhang Z:
Role of bone morphogenetic proteins and their antagonists in
healing of bone fracture. Front Biosci (Landmark Ed). 14:2878–2888.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hsu DR, Economides AN, Wang X, Eimon PM
and Harland RM: The Xenopus dorsalizing factor Gremlin identifies a
novel family of secreted proteins that antagonize BMP activities.
Mol Cell. 1:673–683. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Topol LZ, Bardot B, Zhang Q, Resau J,
Huillard E, Marx M, Calothy G and Blair DG: Biosynthesis,
post-translation modification, and functional characterization of
Drm/Gremlin. J Biol Chem. 275:8785–8793. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Karagiannis GS, Musrap N, Saraon P, Treacy
A, Schaeffer DF, Kirsch R, Riddell RH and Diamandis EP: Bone
morphogenetic protein antagonist gremlin-1 regulates colon cancer
progression. Biol Chem. 396:163–183. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Khokha MK, Hsu D, Brunet LJ, Dionne MS and
Harland RM: Gremlin is the BMP antagonist required for maintenance
of Shh and Fgf signals during limb patterning. Nat Genet.
34:303–307. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lappin DW, McMahon R, Murphy M and Brady
HR: Gremlin: An example of the re-emergence of developmental
programmes in diabetic nephropathy. Nephrol Dial Transplant. 17
Suppl 9:S65–S67. 2002. View Article : Google Scholar
|
|
24
|
Bardot B, Lecoin L, Fliniaux I, Huillard
E, Marx M and Viallet JP: Drm/Gremlin, a BMP antagonist, defines
the interbud region during feather development. Int J Dev Biol.
48:149–156. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Michos O, Panman L, Vintersten K, Beier K,
Zeller R and Zuniga A: Gremlin-mediated BMP antagonism induces the
epithelial-mesenchymal feedback signaling controlling metanephric
kidney and limb organogenesis. Development. 131:3401–3410. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gazzerro E, Smerdel-Ramoya A, Zanotti S,
Stadmeyer L, Durant D, Economides AN and Canalis E: Conditional
deletion of gremlin causes a transient increase in bone formation
and bone mass. J Biol Chem. 282:31549–31557. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zuo B, Zhu J, Li J, Wang C, Zhao X, Cai G,
Li Z, Peng J, Wang P, Shen C, et al: microRNA-103a functions as a
mechanosensitive microRNA to inhibit bone formation through
targeting Runx2. J Bone Miner Res. 30:330–345. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Diefenderfer DL, Osyczka AM, Reilly GC and
Leboy PS: BMP responsiveness in human mesenchymal stem cells.
Connect Tissue Res. 44 Suppl 1:S305–S311. 2003. View Article : Google Scholar
|
|
30
|
Osyczka AM, Diefenderfer DL, Bhargave G
and Leboy PS: Different effects of BMP-2 on marrow stromal cells
from human and rat bone. Cells Tissues Organs. 176:109–119. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wellbrock J, Harbaum L, Stamm H, Hennigs
JK, Schulz B, Klose H, Bokemeyer C, Fiedler W and Lüneburg N:
Intrinsic BMP antagonist gremlin-1 as a novel circulating marker in
pulmonary arterial hypertension. Lung. 193:567–570. 2015.
View Article : Google Scholar : PubMed/NCBI
|
